Revance Announces Departure of Chief Financial Officer

Following Ms. Silvernail’s resignation, certain members of management and the Company’s existing finance team will assume the duties and responsibilities of the office on an interim basis.

Revance is initiating a search for its next Chief Financial Officer, who will play an important role as the Company prepares for the commercialization of its lead product candidate, DaxibotulinumtoxinA for Injection (RT002).

About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with plans to initiate studies in upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180529005411/en/